Group items tagged

The UK government has extended the restrictions on prescribing and supplying of gonadotrophin releasing hormone (GnRH) analogues, commonly referred to as puberty blockers, for those under 18 until the end of the year. These regulations, initially set to expire on 26 November, prohibit any new under-18 patients from beginning puberty suppression treatment for gender dysphoria outside designated specialist NHS services. The government passed the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (Extension) (No. 2) Order 2024 on 6 November, citing health safety concerns to prevent potential serious risks. Children and young people under 18 already using these medicines may continue treatment through a UK-registered prescriber, though prescriptions generally require an 'SLS' endorsement by the prescriber. Prescriptions issued after 3 June 2024 by an EEA or Swiss prescriber remain invalid for these purposes.

Hi friends, today I'll post a brief review on the hormonal assays used for the diagnosis of pregnancy.The hormonal assays that can be used for pregnancy diagnosis are HCG[human chorionic gonadotrophin],progesterone & early pregnancy

We offer pregnancy tests at our Clinic by a choice of blood test and urine test. All pregnancy tests measure the amount of human chorionic gonadotrophin (hCG), the pregnancy hormone, in your body.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating: